10-Q: Inotiv Inc. Reports Q2 2024 Results Amidst Restructuring and Market Challenges

Inotiv Inc. reports a net loss for Q2 2024, impacted by decreased revenue in its Research Models and Services segment and a charge related to an agreement in principle with the Department of Justice.

Summary

• Inotiv Inc. reported a consolidated net loss of $48.1 million for the three months ended March 31, 2024, compared to a net loss of $9.6 million for the same period in 2023.
• The company's revenue decreased to $119.0 million in Q2 2024 from $151.5 million in Q2 2023, primarily due to a $32.1 million decline in revenue from the Research Models and Services (RMS) segment.
• The RMS segment experienced a significant drop in revenue due to lower non-human primate (NHP) sales, which decreased by $26.2 million.
• The Discovery and Safety Assessment (DSA) segment saw a slight decrease in revenue of $0.4 million, with a decrease in discovery services revenue offset by an increase in safety assessment service revenue.
• The company accrued an estimated $26.5 million charge related to an agreement in principle with the Department of Justice, which is reflected in other operating expenses.
• Inotiv has taken steps to improve liquidity, including site consolidations and cost reductions, and has amended its credit agreement to reinstate its ability to borrow under its revolving credit facility.
• The company is working on further route optimization projects designed for further efficiencies and cost reductions.
• The company's book-to-bill ratio for DSA services was 0.77x for the quarter.
• The DSA backlog was $142.1 million at March 31, 2024, down from $145.7 million at March 31, 2023.

Sentiment

Score: 3

Explanation: The document presents a challenging financial situation with significant losses and revenue declines, coupled with ongoing legal and operational issues. While the company is taking steps to address these challenges, the overall outlook is negative.

Positives

• The company has taken steps to improve its liquidity, including negotiating an amendment to its Credit Agreement to reinstate its ability to borrow under its revolving credit facility.
• The company has implemented several initiatives to reduce operating and investing costs, including site consolidation plans.
• The company completed the in-house integration of its North American transportation operations in Q2 2024, which is expected to achieve key efficiencies.
• The company has identified and extensively audited multiple additional sources of purpose-bred animals that can be made available for life-saving medical research which has allowed the Company to diversify our sourcing of NHPs outside of Cambodia.

Negatives

• The company experienced a significant decrease in revenue in its RMS segment, primarily due to lower NHP sales.
• The company reported a substantial net loss of $48.1 million in Q2 2024, compared to a net loss of $9.6 million in Q2 2023.
• The company accrued a $26.5 million charge related to an agreement in principle with the Department of Justice.
• The company has yet to see a meaningful increase in demand from biotech clients despite an increase in U.S. biotech funding in the first calendar quarter of 2024.
• The company's DSA backlog decreased from $145.7 million at March 31, 2023 to $142.1 million at March 31, 2024.

Risks

• The company's ability to continue as a going concern is in substantial doubt.
• The company's revenue and related operating margins may not increase, which could result in non-compliance with financial covenants under the Credit Agreement.
• The company may not be able to raise additional capital or obtain amendments to its Credit Agreement.
• The company is dependent on the importation of NHPs from suppliers located outside the U.S., and legal issues related to these suppliers could impact the business.
• The company is involved in legal proceedings that could adversely affect its business, financial condition, and results of operations.
• The company is subject to government investigations, inquiries, and actions, which could have a material adverse impact on its operations, financial condition, and cash flows.

Future Outlook

The company believes it has sufficient liquidity to satisfy its current obligations for the next twelve months, but there is no assurance that the company will experience an increase in revenue for the remainder of the 2024 fiscal year. The company plans to request amendments to the Credit Agreement and may consider seeking additional financing.

Management Comments

• The company believes the actions taken and investments made in recent periods form a solid foundation upon which we can continue to build.
• The company plans to continue its efforts to optimize its capital allocation and expense base, which reduced our cash expenses in the three and six months ended March 31, 2024 compared to the three and six months ended March 31, 2023, and which are expected to continue to reduce cash expenses in the remainder of fiscal 2024 and into fiscal 2025.
• The Company also continues to collaborate with its lenders with regard to its current business conditions.

Industry Context

The decrease in NHP supply has driven up pricing and caused some studies to be shifted outside of the U.S. The decrease in biotech funding has also contributed to a reduced demand for preclinical studies.

Comparison to Industry Standards

• The document does not provide specific details on industry standards for comparison.
• However, the document notes that NHP imports into the U.S. for drug discovery significantly declined from 2022 to 2023, which is a broader industry trend.
• The document also mentions that decreased biotech funding has contributed to a reduced demand for preclinical studies, which is a trend affecting the CRO industry.

Legal Proceedings

• The company is involved in a securities class action lawsuit and derivative securities lawsuits.
• The company has reached an agreement in principle with the Department of Justice to resolve an investigation.
• The company is subject to a formal order of investigation from the SEC regarding its importation of NHPs from Asia.

Related Party Transactions

• The company has seller notes outstanding to Bolder BioPath, Preclinical Research Services, Histion and Protypia.

Stakeholder Impact

• Shareholders are negatively impacted by the company's poor financial performance and the substantial doubt about its ability to continue as a going concern.
• Employees may be affected by workforce reductions and site consolidations.
• Customers may experience disruptions due to the company's operational challenges and supply chain issues.
• Creditors face increased risk due to the company's financial instability and potential non-compliance with debt covenants.
• Suppliers may be impacted by the company's cost-cutting measures and potential financial difficulties.

Next Steps

• The company plans to continue its efforts to optimize its capital allocation and expense base.
• The company plans to continue to invest in its DSA capacity and added to its service offerings.
• The company plans to request amendments to the Credit Agreement.
• The company may consider seeking additional financing and evaluating financing alternatives to meet its cash requirements for the next 12 months.

Key Dates

Keywords

Inotiv, contract research organization, non-human primates, NHP, research models, drug discovery, preclinical studies, biotech funding, Department of Justice, credit agreement, liquidity, restructuring, site consolidation